Valproate use in women: minimising the risks
You must score at least 70% in this module to pass. Ensure you have read ‘Valproate use in women: minimising the risks’ before attempting to complete the module.
This module can be taken up to three times. Once you have passed, you can view the correct answers and download a certificate as a record of your learning.
Additional CPD modules are available in the ‘My CPD’ section of your account.
Quiz Summary
0 of 15 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 15 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- Current
- Review
- Answered
- Correct
- Incorrect
- Question 1 of 15
1. Question
According to a survey conducted in 2017 by several epilepsy charities, what percentage of epileptic women aged 16–50 years had not been informed of the risks of taking valproate during pregnancy?
CorrectIncorrect - Question 2 of 15
2. Question
Which of the following (in infants) is not associated with in utero exposure to valproate?
CorrectIncorrect - Question 3 of 15
3. Question
What is the risk of congenital malformations when valproate is used in pregnancy?
CorrectIncorrect - Question 4 of 15
4. Question
Which of the following forms of contraceptive are considered highly effective?
CorrectIncorrect - Question 5 of 15
5. Question
Every woman or girl of childbearing potential must be enrolled on a pregnancy prevention programme (PPP), except those who:
CorrectIncorrect - Question 6 of 15
6. Question
Every time valproate is supplied to a woman or girl of childbearing potential, a pharmacist must ensure the patient is provided with a:
CorrectIncorrect - Question 7 of 15
7. Question
In an audit of 6,480 community pharmacies between February and March 2019, the Company Chemist’s Association found that:
CorrectIncorrect - Question 8 of 15
8. Question
A woman of childbearing potential presents you with a one month prescription for valproate. You establish that she has not had an annual specialist review in 18 months, she is on highly effective contraception and understands the risks of valproate in pregnancy. How should you handle this situation?
CorrectIncorrect - Question 9 of 15
9. Question
It is recommended that valproate is supplied in the original container. When would it be appropriate for pharmacists to dispense valproate outside of the original packaging?
CorrectIncorrect - Question 10 of 15
10. Question
When should pharmacists refer a woman or girl of childbearing potential prescribed valproate back to the prescriber as a matter of urgency?
CorrectIncorrect - Question 11 of 15
11. Question
The Faculty of Sexual and Reproductive Healthcare issued guidance for effective contraception during the COVID 19 pandemic. It states that:
CorrectIncorrect - Question 12 of 15
12. Question
When should pharmacies supply the patient guide for valproate when dispensed for a woman or girl of childbearing age?
CorrectIncorrect - Question 13 of 15
13. Question
Regarding real-life challenging scenarios, which of the following is true of people taking valproate?
CorrectIncorrect - Question 14 of 15
14. Question
Under Driver and Vehicle Licensing Authority regulations, women who are changing antiepileptic drugs will need to be advised to stop driving:
CorrectIncorrect - Question 15 of 15
15. Question
Which of the following is not associated with suddenly stopping valproate in a person with epilepsy:
CorrectIncorrect